X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs DR. REDDYS LAB - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD DR. REDDYS LAB WYETH LTD/
DR. REDDYS LAB
 
P/E (TTM) x 27.7 28.2 98.3% View Chart
P/BV x 5.3 3.5 153.8% View Chart
Dividend Yield % 1.3 0.8 168.0%  

Financials

 WYETH LTD   DR. REDDYS LAB
EQUITY SHARE DATA
    WYETH LTD
Mar-13
DR. REDDYS LAB
Mar-18
WYETH LTD/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,0442,788 37.5%   
Low Rs8181,902 43.0%   
Sales per share (Unadj.) Rs298.6860.8 34.7%  
Earnings per share (Unadj.) Rs57.257.1 100.3%  
Cash flow per share (Unadj.) Rs58.4122.0 47.9%  
Dividends per share (Unadj.) Rs17.0020.00 85.0%  
Dividend yield (eoy) %1.80.9 214.0%  
Book value per share (Unadj.) Rs249.5757.7 32.9%  
Shares outstanding (eoy) m22.72165.91 13.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.12.7 114.5%   
Avg P/E ratio x16.341.1 39.6%  
P/CF ratio (eoy) x15.919.2 82.9%  
Price / Book Value ratio x3.73.1 120.6%  
Dividend payout %29.735.0 84.7%   
Avg Mkt Cap Rs m21,157389,034 5.4%   
No. of employees `0000.523.5 2.1%   
Total wages/salary Rs m40032,149 1.2%   
Avg. sales/employee Rs Th13,787.46,070.8 227.1%   
Avg. wages/employee Rs Th813.01,366.6 59.5%   
Avg. net profit/employee Rs Th2,643.3402.5 656.7%   
INCOME DATA
Net Sales Rs m6,783142,810 4.7%  
Other income Rs m3531,552 22.7%   
Total revenues Rs m7,136144,362 4.9%   
Gross profit Rs m1,61723,512 6.9%  
Depreciation Rs m2710,772 0.2%   
Interest Rs m6788 0.7%   
Profit before tax Rs m1,93813,504 14.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0344 0.0%   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6324,380 14.4%   
Profit after tax Rs m1,3019,468 13.7%  
Gross profit margin %23.816.5 144.8%  
Effective tax rate %32.632.4 100.6%   
Net profit margin %19.26.6 289.2%  
BALANCE SHEET DATA
Current assets Rs m6,984104,984 6.7%   
Current liabilities Rs m2,05668,938 3.0%   
Net working cap to sales %72.625.2 287.8%  
Current ratio x3.41.5 223.1%  
Inventory Days Days9974 133.5%  
Debtors Days Days24104 23.1%  
Net fixed assets Rs m244104,385 0.2%   
Share capital Rs m227830 27.4%   
"Free" reserves Rs m5,441124,886 4.4%   
Net worth Rs m5,668125,716 4.5%   
Long term debt Rs m2525,089 0.1%   
Total assets Rs m7,901225,443 3.5%  
Interest coverage x353.318.1 1,948.1%   
Debt to equity ratio x00.2 2.2%  
Sales to assets ratio x0.90.6 135.5%   
Return on assets %16.54.5 363.3%  
Return on equity %22.97.5 304.7%  
Return on capital %34.09.7 350.8%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1572,623 0.0%   
Fx outflow Rs m2,67718,916 14.2%   
Net fx Rs m-2,66253,707 -5.0%   
CASH FLOW
From Operations Rs m92318,030 5.1%  
From Investments Rs m317-14,883 -2.1%  
From Financial Activity Rs m-481-4,440 10.8%  
Net Cashflow Rs m759-1,236 -61.4%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 5.4 209.3%  
FIIs % 7.2 35.3 20.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 30.4 15.3 198.7%  
Shareholders   21,978 75,885 29.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   VENUS REMEDIES  ORCHID PHARMA LTD  GSK PHARMA  J.B.CHEMICALS  SHASUN PHARMA  

Compare WYETH LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Recover; Sensex Ends 77 Points Higher(Closing)

Indian share markets witnessed buying interest during closing hours and ended on a positive note. Gains were seen in the metal sector.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - PIRAMAL ENTERPRISES COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS